Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine

Lancet. 1993 Jan 2;341(8836):63. doi: 10.1016/0140-6736(93)92546-6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Debrisoquin / administration & dosage*
  • Debrisoquin / pharmacokinetics*
  • Female
  • Humans
  • Hydroxylation
  • Metabolic Diseases / genetics*
  • Neurotic Disorders / drug therapy*
  • Polymorphism, Restriction Fragment Length

Substances

  • Debrisoquin